Pipeline
Our oncology pipeline includes multiple dual-payload immunotherapies and targeted vector immunotherapies.
Our lead candidate, GEN2, carries a proprietary pro-drug facilitated cancer killing gene, Herpes Simplex Virus enhanced Thymidine Kinase (HSV-eTK) and an immunocytokine, Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF). Our HSV-eTK gene has been engineered in-house for increased cancer cell killing. These therapeutic genes work together to release patient specific neoantigens and induce the immune system to activate a persistent and systemic response against the cancer.
GEN-1013 utilizes the same vector platform, but codes for a different cytokine, Interleukin-12 (IL-12).
GEN-0x00 is our targeting program, in which the surface proteins can be modified to target desired cancer cell surface receptors.
Additional assets are under development for infectious disease applications.
Pipeline
Candidate
Indication
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase 1
Candidate
Indication
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase 1
Candidate
Indication
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase 1
Candidate
Indication
Discovery
Preclinical
IND-
Enabling
IND
Clinical - Phase 1
Candidate
GEN-4035